The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia's Authorised Prescriber Scheme, where no serious adverse ...
Controlled Extraction of Phosphorylatable Psychoactive Alkaloids," issued this month, adding to the intellectual property ...
The approval to initiate this Phase 2 clinical trial represents a pivotal moment in the clinical development of Optimi's GMP natural psilocybin extract capsules. Building on its established status as ...
Psilocybin is known as the active compound in so-called “magic mushrooms”, yet most psilocybin used in clinical trials today is synthesized in laboratories without the use of biological material. As ...
As many states and municipalities around the country grapple with the ever-increasing popularity of psilocybin-based products, a few have staked out leading positions in what may be the next wave of ...
Colorado could limit the state’s emerging magic mushroom industry to one strain and severely restrict the use of psilocybin extractions, according to the final draft of proposed natural medicine ...
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results